Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Modular training resources for bioimage analysis.

Journal of microscopy·2026
Same author

Deciphering Mental Illness: Neurons vs. Neuroglia.

Journal of clinical psychopharmacology·2026
Same author

A Material Roadmap for Translational and Sustainable Point-of-Care Diagnostics Through Bacterial Cellulose: A Comprehensive Review.

ACS applied bio materials·2026
Same author

Liposomal Methylglyoxal Targets Virulence and Intracellular Persistence to Overcome Amphotericin B Resistance in <i>Cryptococcus neoformans</i>.

International journal of molecular sciences·2026
Same author

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

Biological psychiatry global open science·2026
Same author

Precision in Planning: Airway Battles in Pediatric Temporomandibular Joint Ankylosis.

Annals of African medicine·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Aishwarya Prasad1, Anshu Arora1, Arun Arora1

  • 1Northwest Clinical Research Center, Bellevue, WA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

胆酶抑制剂 (AChEIs) 在改善阿尔茨海默病 (AD) 症状方面比单克隆抗体 (mAbs) 有更大的疗效,尽管mAbs被研究了更长的时间. 需要进一步的研究才能进行直接比较.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经学 神经学
  • 药理学 药理学 是一个学科.
  • 临床研究 临床研究

背景情况:

  • 现有的阿尔茨海默病 (AD) 研究表明,与胆酶抑制剂 (AChEIs) 相比,单克隆抗体 (mAbs) 具有适度的益处.
  • 在mAbs和ACHEI之间的直接比较疗效数据是有限的.
  • 这项研究旨在使用现有证据来比较这些药物类别的疗效.

研究的目的:

  • 为了比较单克隆抗体 (mAbs) 和胆酶抑制剂 (AChEIs) 在治疗阿尔茨海默病中的疗效.
  • 根据FDA数据分析这些药物类别的风险益处概况.
  • 通过ADAS-Cog尺度来评估ADD药物的疗效.

主要方法:

  • 分析了来自FDA档案的有效性数据 (到2024年10月).
  • 包括5种药物 (多纳尼马布,莱卡尼马布,阿杜卡努马布,多纳佩西尔,加兰塔明),涉及11,122名受试者.
  • 选择了使用ADAS-Cog尺度评估的药物;由于结果措施不同,Memantine被排除在外.

主要成果:

  • 胆酶抑制剂 (AChEIs) 在ADAS-Cog尺度上与安慰剂在25.5周内平均差异为-2.82.
  • 单克隆抗体 (mAbs) 在77.3周的ADAS-Cog尺度与安慰剂的平均差异为-1.08.
  • 与安慰剂相比,所有分析的药物都显示出了统计学上显著的改善.

结论:

  • 虽然这两种药物类别都显示出统计学上显著的疗效,但ACHEI被批准用于中度至重度的AD,mAbs用于轻度认知障碍或轻度痴呆.
  • 在ADAS-Cog尺度版本中的差异 (例如,ADAS-Cog 11与13) 复杂化了直接的疗效比较.
  • 需要进一步的研究来最终评估较新的mAbs与安慰剂和现有治疗方法的比较疗效.